Oncology News | pharmaphorum

News

NICE backs Pfizer’s Talzenna for advanced breast cancer

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recomm

News

BridgeBio raises $1.25bn, and other biotech financings

Our round-up of recent biotech financings is headed by a massive $1.25 billion round for genetic medicines specialist BridgeBio Pharma, with smaller rounds for Tr1X, Coman

News

FDA clears AI skin cancer detection device from DermaSensor

Medtech company DermaSensor has claimed FDA approval for a handheld device, powered by artificial intelligence (AI), that can be used to detect skin cancer at the point of

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.

NICE backs Pfizer’s Talzenna for advanced breast cancer

BridgeBio raises $1.25bn, and other biotech financings

FDA clears AI skin cancer detection device from DermaSensor

DISCO dances out of the shadows with €20m for ‘surfaceome’

Roche bags EU okay for subcutaneous Tecentriq

Update: Orion buys stake in LegoChem as biotech push goes on

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks